Moreover, pharmacological inhibition of NF-κB in T2D has been shown to reduce mitochondrial abnormalities and reduce myocardial oxidative stress (Mariappan et al., 2010). The gene discussed is NFKB1; the disease is type 2 diabetes mellitus.